Innovative Fixation System for a Leadless Pacemaker in the Atrial Appendage
Technology Introduction:
his technology introduces a world-first atrial appendage fixation device for leadless pacemakers. Delivered via transfemoral access, it anchors securely in the right atrial appendage to prevent device dislodgement and perforation. The nitinol-based structure supports device replacement and is compatible with existing systems such as Medtronic Micra AV2 and Abbott Aveir DR. It is designed to be FDA-registered as an accessory, offering a safer and scalable solution for dual-chamber leadless pacing
Industry Applicability:
This novel atrial appendage fixation device enables safe right atrial implantation of leadless pacemakers. Compatible with systems like Micra AV2 and Aveir DR, it addresses a critical unmet need in dual-chamber pacing. With regulatory positioning as an FDA “accessory,” it offers accelerated commercialization and strong licensing potential. The technology is well-suited for integration or spin-off development targeting high-growth cardiovascular markets.
his technology introduces a world-first atrial appendage fixation device for leadless pacemakers. Delivered via transfemoral access, it anchors securely in the right atrial appendage to prevent device dislodgement and perforation. The nitinol-based structure supports device replacement and is compatible with existing systems such as Medtronic Micra AV2 and Abbott Aveir DR. It is designed to be FDA-registered as an accessory, offering a safer and scalable solution for dual-chamber leadless pacing
Industry Applicability:
This novel atrial appendage fixation device enables safe right atrial implantation of leadless pacemakers. Compatible with systems like Micra AV2 and Aveir DR, it addresses a critical unmet need in dual-chamber pacing. With regulatory positioning as an FDA “accessory,” it offers accelerated commercialization and strong licensing potential. The technology is well-suited for integration or spin-off development targeting high-growth cardiovascular markets.
Industrial Applications:
-
Chang Gung Medical Foundation
In the early 1970s, healthcare systems in Taiwan were undergoing a crisis. Sick and injured people faced numerous obstacles in receiving adequate medical help. In addition, the Medical schools and colleges were severely lacking in resources and training facilities prompting many would-be doctors to go abroad for further training, many of which would not return. This resulted in an outflow of national talent and further depletion of adequate personnel to improve the healthcare system. Prompted by a personal tragic experience involving the medical treatment of his own father, and driven by a sense of mission to give back to society, Mr Wang Yung-ching of the Formosa Plastics Group founded the Chang Gung Memorial Hospital Group in 1973.
Additional Information
Pavilion：Future Tech Bio-tech, New Drugs & Medical Devices FM20
Exhibiting Entity：National Science and Technology Council
Application Category：Biotechnology and Medicine
More
Pavilion：Future Tech Bio-tech, New Drugs & Medical Devices FM20
Exhibiting Entity：National Science and Technology Council
Application Category：Biotechnology and Medicine
Patents：
US11433244B2
